Skip to content

Study of the Prognostic Value of Musculoskeletal Ultrasound in Adults With Chikungunya

Study of the Prognostic Value of Musculoskeletal Ultrasound in Adults With Chikungunya

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02281123
Acronym
EchoCHIK
Enrollment
200
Registered
2014-11-03
Start date
2014-07-31
Completion date
2016-01-31
Last updated
2015-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infected by Chikungunya Virus

Brief summary

Chikungunya is a viral disease transmitted by mosquitoes whose clinical feature is the early joint damage. Approximately 8% of patients have chronic arthropathy resembling to the rheumatoid polyarthritis. The EchoCHIK study we propose is in the context of the epidemic in Martinique which began in January 2014. It should give a better understanding of arthritis and juxtaarticular of CHIK and look for signs that may allow ultrasound predict the evolution of chronic arthropathy of CHIK.

Interventions

OTHERSF36 (QQoL)

use of quality of life questionnaire (SF 36) ( at enrollment visit, at 3 month, at 6 month and at12 month for the following visits)

Sponsors

University Hospital Center of Martinique
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
45 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age at onset of symptoms ≥ 45 years 2. Seen in consultation at the University Hospital of Fort-de-France 3. Suspected chikungunya infection (fever and sudden onset of joint pain affecting the wrists, hands, ankles or knees) 4. Duration of symptoms suggestive of infection chikungunya less than or equal to 10 days 5. Presence of joint pain on the day of inclusion 6. No history of inflammatory arthritis 7. Absence of steroidal or non-steroidal anti-inflammatory drugs taken within two weeks prior to inclusion 8. Ability to participate in the study throughout its duration (12 months) 9. Patient affiliated or beneficiary of a social health care. 10. Acceptance to participate in the study and monitoring proposed and signed informed consent

Exclusion criteria

1. Age at onset of symptoms \<45 years 2. Duration of symptoms suggestive of chikungunya for more than 10 days 3. Lack of joint pain on the day of inclusion 4. History of inflammatory arthritis Nonsteroidal anti-inflammatory drugs or 5. Taking in the two weeks preceding the inclusion 6. Inability to participate in the study throughout its duration (12 months) 7. Patient is not affiliated or beneficiary of a social health care. 8. Refusal to participate in the study or to sign a consent

Design outcomes

Primary

MeasureTime frameDescription
Presence of sonographic signs observed during the initial scan: periarticular infiltration, effusion, positive Doppler, erosions.enrollement visitProgression to chronic form defined by the persistence or recurrence of muscle symptoms (myalgia) and joints (arthralgia, arthritis) more than two months after the onset of symptoms of acute phase.

Secondary

MeasureTime frame
Presence of clinical and sonographic signs observed at each visit: arthralgia, arthritis clinics, periarticular infiltration, effusion, positive Doppler erosions.1 month, 3 month, 6 month and 12 month after the first symptoms of infection by chikungunya virus

Countries

Martinique

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026